

# Subject Index

- A**  
 Abbott TDX™, 339  
 Abuse, personal, 181  
 Acinar cells, 17  
 Acoustic stressor, 276  
*Actinobacillus actinomycetemcomitans*, 209  
 Acute-phase protein, 277  
 Adenoid hyperplasia, 296  
 Adult periodontitis, 209  
 Advanced destructive periodontitis, 212  
 Age  
   female fecundity and, 168  
   salivary immunoglobulin A secretion and, 296  
 AIDS, infant, 195  
 Alcohol, 92  
 Amphetamine, 93  
 Amylase, 13  
 Androgens, salivary, measurement of, 146  
 Androstenedione, 147  
 Anion, secreted, 27  
 Anti-hepatitis A, 289  
 Antibodies, salivary, 7  
   in dental diseases, 202  
 Anticancer drugs, salivary excretion of, 319  
 Antigens, salivary, 7  
 Autoantibodies, salivary, 241  
 Autoimmune disease, 235  
   salivary measurements in, 238
- B**  
 Back pain, chronic, 308  
 Bacterial aggregation, 283  
 Barbiturates, 95  
 Bayes' formula, 79  
 Behavior, salivary testosterone and, 177, 179  
 Benzodiazepines, 97  
 Biological markers  
   salivary, plaque-mediated diseases and, 260  
   theoretical and practical concepts of, 63  
 Blood ethanol levels, 293  
 Buffer capacity, salivary, 259
- C**  
 $\text{Ca}^{2+}$ , fluid secretion and, 19  
 Caffeine, 98  
 Caries, 266  
   early experience of, 205  
   postmenopausal estrogen treatment and, 287  
   risk assessment in, 302  
   salivary antibody in, 208  
   salivary function in relation to, 234  
   vaccines for, 209  
 Caries activity, evaluation of, 257  
 Carious lesions, 204  
 Catecholamine release, 276  
 CD4+ T cells, 210  
 Chair-side tests, 252  
 Children, saliva drug monitoring in, 53  
 $\text{Cl}^-/\text{HCO}_3^-$  exchange, 27  
 Clearance, salivary, 41  
 Clinical laboratory instrumentation, recent advances in, 78  
 Cocaine, 99  
 Codeine, 111  
 Collection, saliva (*see also* Devices, collection), 86, 219  
   drugs of abuse and, 311  
   methods for, 72  
   therapeutic drugs and, 311  
 Common mucosal immune system, saliva as manifestation of, 184  
 Congenital adrenal hyperplasia, 148  
 Contests, winning, 180  
 Cost/benefit analysis of home testing, 84  
 Cotinine, 332  
 Cyclic AMP  
    $\beta$ -adrenergic receptor stimulation of, 19  
   reactions of in saliva, 299  
 Cystatin C, 280  
 Cystic fibrosis  
   salivary gland functional alterations in, 235  
   salivary studies in, 4
- D**  
 Dehydroepiandrosterone sulfate, 147  
 Dental diseases, significance of salivary antibody in, 202  
 Dental plaque, value of salivary monitoring of, 252  
 Depression, psychological, 181  
 Devices, collection (*see also* device names), 75  
   bilateral, 317  
 Diabetes mellitus, 236  
 Diagnosis, salivary  
   developing new test for, 78  
   promises of, 1  
 Diagnostic tests (*see* Tests, diagnostic)

Diathesis, 2  
 Diffusion sink, 128  
 Digitalis, toxicity of, 5  
 Dilantin™, 339  
 Dioxin, 68  
 Dip-slide technique, 257  
 Dipstick method, 272  
 Disease monitoring, 234  
 Doctor-office laboratory testing, 81  
 Dribbled saliva, 219  
 Drug concentrations, salivary, 88  
 Drug distribution, pharmacokinetic principles of, in saliva, 36  
 Drug levels in parotid saliva, 317  
 Drug monitoring, 6  
   role of saliva in, 86  
   saliva as a substitute for blood in, 128  
   therapeutic, 48, 86  
 Drugs, clinical correlates of, in saliva, 48  
 Drugs of abuse  
   saliva collection for measurement of, 311  
   saliva testing for, 91

**E**lderly, saliva drug monitoring in, 53  
 Electrolytes, 241  
 Energetics, relationship of, to female reproductive function, 169  
 Enzyme immunoassay, 314  
   cotinine, 332  
 Enzyme-linked immunosorbent assays, 340  
 Epilepsy, 283  
 Estradiol, 154  
 Estrinol, 154  
 Estrogen, postmenopausal, 286  
 Estrogens, salivary, measurement of, 146  
 Ethanol, 293

**F**alse positive/negative test results (*see* Tests, diagnostic)  
 Flow rate, salivary  
   concentration of saliva affected by, 133  
   effect of estrogen supplementation on, 286  
   evaluation of caries susceptibility from, 258  
   factors affecting, 73  
   immunoglobulin A secretion and, 296  
   penetration of organic substances and, 87  
   Sjögren's syndrome and, 242  
 Fluorapatite ion product, 302  
 Forensic drug testing, 121

**G**as chromatography/mass spectrometry, 332  
 Gingival crevicular fluid, 204  
 Gingivitis, cystatin activity in, 280

Gland  
   submandibular, 325  
   Von Ebner's, 322  
 Glands, salivary, 24  
   permeability of, 87  
 Glycoproteins, 283  
 Graft-versus-host disease, 238

**H***elicobacter pylori*, 340  
 Hepatitis A, 334  
   simple and reliable tests for, 216  
 Hepatitis A vaccines, 289  
 Hepatitis B, 334  
   simple and reliable tests for, 216  
 Hepatitis B surface antigen, 334  
   rapid saliva test for, 272  
 Hepatitis C, 334  
 Heroin, 108  
 HIV, 236  
   perinatal, 195  
   simple and reliable salivary tests for, 216  
 HIV antibody, 314  
 Hormone monitoring, 6

**I**mmunoglobulin A, 195  
 Immunoglobulin A molecules, structural aspects of, 184  
 Immunoglobulin G antibody capture enzyme immunoassay, 226  
 Immunoglobulin G antibody capture radioimmunoassay, 226  
 Immunoglobulin G levels, 330  
 Immunoglobulins, salivary, 241  
 Immunological correlates in periodontal diseases, 209  
 Immunoregulatory circuits, 211  
 Infertility, 167  
 Inhalants, 104  
 Intravenous drug users, 228

**J** chain, 202  
 Juvenile periodontitis, localized, 209

**L**actobacilli, 257, 302  
 Lactoferrin, 241  
 Lead, levels of, in saliva, 67  
 Luteal phase deficiency, 164-165  
 Lysergic acid diethylamide, 105  
 Lysozyme, 241

**M**acromolecules, salivary, 11  
 Marijuana, 106

Measles, 227  
Menstrual cycle, 156  
Methamphetamine, 93  
 $\beta_2$ -Microglobulin, 242  
Mood states, 296  
Morphine, 111  
Mucins, 11  
Multiple sclerosis, 305  
Mumps, 227  
Mutans streptococci, 204, 258, 302

**N**  
 $\text{Na}^+/\text{H}^+$  exchange, 27  
 $\text{Na}^+-\text{K}^+-2\text{Cl}^-$  cotransport, 25  
Neurotoxicology, 62  
Neurotransmitter stimulation, 17  
Nicotine, 119

**O**  
OmniSal™, 221, 314  
Opioids, 108  
Oral bacteria, effect of estrogen supplementation on, 286  
Oral diseases  
  saliva for diagnosis of, 265  
  salivary monitoring in, 234  
Oral fungal infections, 267  
OraSure™, 221  
OraSure™ oral fluid  
  comparative study of saliva and, 330  
  cotinine in, 332  
  *Helicobacter pylori* antibody detection and, 340  
  hepatitis A, B, and C and, 334  
  therapeutic drug monitoring using, 337  
Ovarian function, 164, 171

**P**  
P450 enzymes, 68  
Parotid gland, 325  
Parotid saliva  
  cyclic AMP reactions in, 299  
  drug levels in, 317  
  juvenile periodontitis and, 211  
  new device for collection of, 274  
Parotid saliva C-reactive protein, 276  
Partition coefficients, 39  
Pathogens, periodontal, 211  
Pediatric saliva testing, 338  
Perinatal HIV diagnosis, practical applications for saliva in, 195  
Periodontal diseases, 266  
  immunological correlates in, 209  
Periodontitis, cystatin activity in, 280  
Permeability of salivary glands, 87  
Peyer's patches, 202  
pH-partition, 39

Pharmacokinetics based on salivary drug concentrations, 88  
Pharmacokinetics of drug distribution in saliva, 36, 49  
Phencyclidine, 117  
Phenytoin (Dilantin™), 339  
Phosphodiesterase activity, 299  
 $pK_a$ , 130  
pH and, 39  
Plasma, immunoreactive substance P values in, 308  
Plasma cells, immunoglobulin A producing, 184  
Plasma steroid levels, 143  
Polymeric immunoglobulin receptor, 202  
*Porphyromonas gingivalis*, 209  
Postmenopause, 286  
Prediction, value of diagnostic procedure for, 79  
Pregnancy, saliva drug monitoring in, 53  
Prevalence, disease, 79  
*Prevotella intermedia*, 210  
Progesterone, salivary, measurements of, 161  
Protein binding, 40, 132  
Proteins, salivary, 305  
Pulsatile progesterone patterns, 171

**Q**  
Quality control, 83

**R**  
Rapidly progressive periodontitis, 210  
Reproductive ecology, 167  
Rice Test, 1  
Rubella, 227

**S**  
Saliva  
  anticancer drugs and, 319  
  blood vs., in drug monitoring, 128  
  caries and, 302  
  clinical correlates of drugs in, 48  
  collection of (see Collection, saliva)  
    devices for (see Devices, collection)  
  common mucosal immune system and, 184  
  cyclic AMP reactions in, 299  
  cystatin C levels of, 280  
  dental plaque and, 252  
  diagnostic tests on, development of, 265  
  dribbled, 219  
  drugs of abuse in, 91  
  ethanol in, 293  
  flow rate of (see Flow rate, salivary)  
  glycoproteins of, 283  
  hepatitis A vaccines and, 289  
  hepatitis B surface antigen and, 272

Saliva (*continued*)

- immunoreactive substance P in, 308
- lead in, levels of, 67
- OraSure™ oral fluid and, 330
- organic solvents in, concentrations of, 67
- parotid (*see* Parotid saliva)
- perinatal HIV diagnosis and, 195
- pharmacokinetic principles of drug distribution in, 36
- progesterone in, measurements of, 161
- public and common scientific images of, 1
- role of, in drug monitoring, 86
- secretion of, 17
- secretory proteins and, 299
- Sjögren's syndrome and, 325
- steroid hormone analysis in, 143
- structure/function studies of, 12
- testosterone in, and behavior, 177
- unstimulated, 72
- whole, infant, 202
- Saliva/plasma ratio, 86
- drugs of abuse and, 102
- factors influencing, 128
- Salivary immunoglobulin A, 296
- Salivary monitoring
  - oral diseases and, 234
  - plaque-mediated disease and, 252
- Salivette™, 128, 221
- Second messenger, Ca<sup>2+</sup> channel activated by, 20
- Secretion
  - fluid, mechanisms for, 24
  - saliva, principles of, 17
- Secretions, pure glandular, 202
- Secretory component, 202
- Secretory immunoglobulin A, 184, 202
- Secretory proteins, 299
- Self-determination, 82
- Self-testing, 83
- Sensitivity, 78, 253
- Sialochemistry, evolution of, 270
- Sialometry, 325
- Signal transduction, 19
- Sjögren's syndrome, 239
  - saliva as diagnostic fluid in, 325
- SLURP cup, 274
- Solvents, organic, in saliva, 67
- Sonar, 276
- Special subjects, saliva drug monitoring in, 53
- Specificity, 78, 253
- Steroid hormone analysis, human saliva and, 143
- Stimulants, 72
- Stimulus-secretion coupling, 27
- Streptococcus mitis*, 204
- Streptococcus salivarius*, 204
- Stress, 296

- Structure/function studies of saliva, 12
- Substance P, immunoreactive, 308
- Suicide, 181
- Summary of conference, 270
- Syntex AccuLevel™ theophylline test, 338
- Systemic disease, 234

- T** helper cells, cloned antigen-specific, 210
- Taste bud cells, 322
- Testosterone, 148
  - salivary, behavior and, 177
- Tests
  - diagnostic (*see also* Sensitivity, Specificity)
    - chair-side, 252
    - doctor-office, 81
    - for drugs of abuse, 91
    - for hepatitis A, 216
    - for hepatitis B, 216
    - for HIV, 216
    - for infant AIDS, 195
    - for oral diseases, 265
    - pediatric, 338
    - quality control of, 83
    - self-administered and evaluated, 83
    - true and false positive/negative results in, 79, 254
  - forensic, 121
- Theophylline, 337
- Therapeutic drug monitoring, 48, 86
  - OraSure™ collection device and, 337
- Therapeutic drugs, saliva collection for measurement of, 311
- Tobacco, 119
- Transfer mechanism, influence of, on saliva/plasma ratio, 129
- Transport
  - regulation of, 31
  - selective, of immunoglobulin A in external secretions, 186
- True positive/negative test results (*see* Tests, diagnostic)

- V**accines for dental caries, 209
- Vallate papilla, 322
- Violence, salivary testosterone and, 178
- Von Ebner's gland, 322

- W**estern blot, 195, 216, 314
- Winning of contests and games, 180

- X**erostomia, 266

- Y**east, salivary, assay of, 259

## Index of Contributors

**A**rchibald, D. W., 195-201  
Atkinson, J. C., 238-251

**B**arriga, G., 314-316  
Bartos, F., 337-339  
Baum, B. J., 17-23  
Beaudreau, C., 272-273  
Beller, M., 334-336  
Bennetts, R. W., 340-342  
Billings, R. J., 302-304  
Bodner, J., 299-301  
Browe, C., 272-273  
Brown, N., 317-318

**C**imlar, B. M., 340-342  
Clemmons, R. M., 272-273  
Cone, E. J., 91-127  
Cordeiro, M. L., 330-331, 332-333  
Covill, P. J., 276-279  
Craig, P. A., 311-313

**D**abbs, J. M., Jr., 177-183  
Davidson, S. L., 332-333, 334-336  
Davis, G., 272-273  
Dawes, C., 265-269

**E**llison, P. T., 161-176  
Epstein, P. M., 299-301  
Erbling, M. C., 340-342  
Ericson, T., 274-275  
Esquire, R. G., 276-279, 299-301

**F**arley, J. J., Jr., 195-201  
Featherstone, J. D. B., 302-304  
Fitchen, J. H., 332-333, 337-339  
Fitzgibbons, D., 314-316  
Fox, P. C., 234-237

**G**alen, E. A., 340-342  
Gaudette, N. D., 332-333  
Goodman, D. B. P., 78-85  
Green, T., 337-339  
Gwinner, L. M., 302-304

**H**aaake, D., 296-298  
Haas, J., 305-307  
Hachisu, R., 299-301  
Haeckel, R., 128-142  
Hand, A. R., 299-301  
Hebert, C. A., 195-201  
Heikkinen, J., 286-288  
Henskens, Y. M. C., 280-282, 283-285  
Hess, M., 296-298  
Hietala, E.-L., 286-288  
Hindahl, M. S., 332-333  
Hines, S. E., 195-201  
Holden, W., 337-339  
Humphrey, P., 272-273  
Hurni, W. M., 289-292

**J**ohnson, B. W., 308-310  
Johnson, J. P., 195-201  
Jusko, W. J., 36-47

**K**allenberg, C. G. M., 325-329  
Kambam, J. R., 308-310  
Kiesow, L. A., 293-295  
Kugler, J., 296-298

**L**armas, M., 252-264, 286-288  
Laufer, D., 289-292  
Leverett, D. H., 302-304  
Levine, M. J., 11-16  
Ligeon, E. E., 325-329  
Ligtenberg, A. J. M., 283-285  
Long, W. B., 293-295

**M**alamud, D., ix-x  
Mandel, I. D., 1-10  
Martinez, R., 322-324  
McAdams, S. A., 330-331  
Mednieks, M. I., 299-301  
Mestecky, J., 184-194  
Miller, W. J., 289-292  
Milsap, R. L., 36-47  
Mundorff, S. A., 302-304

**N**adimi, H., 322-324  
Nair, P., 195-201

Naukam, R. J., 308-310  
Nauta, J. M., 325-329  
Navazesh, M., 72-77  
Nieuw Amerongen, A. V., 280-282, 283-285  
Nikkels, P. G. J., 325-329  
Nordlund, Å., 274-275  
North, L. M., 332-333

**P**anders, A. K., 325-329  
Parris, W. C. V., 308-310  
Parry, J. V., 216-233  
Pederson, E. D., 276-279  
Piacentini, S. C., 334-336  
Pietz, K., 305-307  
Proskin, H. M., 302-304

**Q**uissell, D. O., 143-145

**R**ama Sastry, B. V., 308-310  
Read, G. F., 146-160  
Riley, C., 319-321  
Ryan, J., 289-292

**S**alinsky, M., 337-339  
Schramm, W., 311-313  
Seymour, E., 314-316  
Shaffer, C. L., 302-304  
Shands, J., 272-273  
Shields, C. P., 302-304  
Siegel, I. A., 86-90  
Silbergeld, E. K., 62-71

Simons, C. T., 293-295  
Slavik, J., 317-318  
Slavik, M., 317-318, 319-321  
Smith, D. J., 202-215  
Smith, P. F., 276-279  
Smith, R. H., 311-313  
Stewart, C., 272-273  
Stramer, S., 314-316  
Strooker, H., 283-285

**T**abak, L. A., 270-271  
Taubman, M. A., 202-215  
Thieme, T. R., 334-336, 337-339  
Toto, P. D., 322-324  
Turner, R. J., 24-35  
Turpin, C. S., 330-331

**V**äänänen, H. K., 286-288  
Van Der Velden, U., 280-282  
Veerman, E. C. I., 280-282, 283-285  
Vissink, A., 325-329

**W**agner, S., 317-318  
Watson, B., 289-292  
Wienholt, M. G., 340-342  
Williams, A., 317-318  
Wilson, J. T., 48-61  
Wu, J., 317-318, 319-321  
Wurster, U., 305-307

**Z**aki, A. E., 299-301

